Cardiovascular Disease Heart Attack Peripheral Arterial Disease 
Heart BMJ
MARCH 12, 2024
Objective Assessment of generalisability of guideline-informing trials on antithrombotic treatment intensification to real-world patients with cardiovascular disease (CVD). Eligible and ineligible patients were compared on baseline characteristics, cardiovascular events, major bleeding and mortality.
DAIC
MAY 16, 2024
A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).
DAIC
JANUARY 23, 2024
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2
Heart BMJ
MARCH 12, 2024
The study aims to evaluate the applicability in the real world of randomised clinical trials (RCT) on antithrombotic treatment in patients with cardiovascular disease (CVD) and peripheral artery disease (PAD).
DAIC
APRIL 5, 2024
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD).
Expert insights. Personalized for you.
40 
Let's personalize your content